Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00499772 |
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with myeloid cancer.
Condition | Intervention | Phase |
---|---|---|
Leukemia Myelodysplastic Syndromes |
Drug: PR1 leukemia peptide vaccine Drug: WT1 126-134 peptide vaccine Drug: incomplete Freund's adjuvant Drug: sargramostim |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Active Control |
Official Title: | Efficacy of WT1 and PR1 Peptide Vaccination for Patients With Low Risk Myeloid Malignancies |
Estimated Enrollment: | 24 |
Study Start Date: | June 2007 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients receive WT1:126-134 and PR1:169-177 peptide vaccines emulsified in incomplete Freund's adjuvant subcutaneously (SC) administered concurrently with sargramostim (GM-CSF) SC once every 2 weeks. In order to monitor the local effects of each vaccine, injections are administered to separate sites that are rotated every 2 weeks. Treatment continues for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with immunological response to one or both peptide vaccines will have the option of receiving an additional 6 boosters of the peptide vaccines at 3 monthly intervals.
After completion of study therapy, patients are followed at weeks 12 and 16.
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Myelodysplastic syndromes (MDS), including 1 of the following FAB histologic subtypes:
AND meets the following criteria:
Acute myeloid leukemia (AML) meeting the following criteria:
Chronic myelogenous leukemia (CML) meeting the following criteria:
Meets 1 of the following criteria:
At least 6 months-3 years since prior allogeneic stem cell transplantation AND demonstrates the following clinical features:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Maryland | |
NIH - Warren Grant Magnuson Clinical Center | Recruiting |
Bethesda, Maryland, United States, 20892-1182 | |
Contact: Clinical Trials Office - NIH - Warren Grant Magnuson Clinical 800-411-1222 |
Principal Investigator: | Quan Le, PhD | National Heart, Lung, and Blood Institute (NHLBI) |
Responsible Party: | NHLBI - Hematology Branch ( Quan Le ) |
Study ID Numbers: | CDR0000558028, NHLBI-07-H-0159 |
Study First Received: | July 10, 2007 |
Last Updated: | December 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00499772 |
Health Authority: | Unspecified |
refractory anemia with ringed sideroblasts refractory anemia de novo myelodysplastic syndromes secondary myelodysplastic syndromes previously treated myelodysplastic syndromes adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (MLL) abnormalities |
adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) chronic phase chronic myelogenous leukemia relapsing chronic myelogenous leukemia |
Precancerous Conditions Chronic myelogenous leukemia Refractory anemia Leukemia, Myeloid, Chronic-Phase Leukemia, Myeloid, Acute Leukemia Preleukemia Anemia, Refractory Neoplasm Metastasis Wilms Tumor Acute myeloid leukemia, adult Congenital Abnormalities Acute myelocytic leukemia |
Myelodysplastic syndromes Hematologic Diseases Myelodysplastic Syndromes Myelodysplasia Wilms' tumor Anemia Myeloproliferative Disorders Acute myelogenous leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Freund's Adjuvant Bone Marrow Diseases |
Neoplasms Pathologic Processes Disease Neoplasms by Histologic Type Immunologic Factors |
Syndrome Physiological Effects of Drugs Adjuvants, Immunologic Pharmacologic Actions |